Molecular Partners AG
SWB:6ML
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Molecular Partners AG
SWB:6ML
|
CH |
|
Z
|
Zhejiang Yankon Group Co Ltd
SSE:600261
|
CN |
|
A
|
Anglo American Platinum Ltd
SWB:RPHA
|
ZA |
Bankruptcy Probability
Molecular Partners AG's probability of bankruptcy is 2.5%, pointing to a small but noticeable default risk. The solvency score is 55/100 — a warning sign of potential financial weakness.
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Molecular Partners AG Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CH |
|
Molecular Partners AG
SIX:MOLN
|
126.8m CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
AbbVie Inc
NYSE:ABBV
|
481.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
220.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences, Inc
NASDAQ:GILD
|
182.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
127.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Moderna Inc
NASDAQ:MRNA
|
78.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
76.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Natera Inc
NASDAQ:NTRA
|
56.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
45.6B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
40.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Molecular Partners AG's probability of bankruptcy is 2.5%, pointing to a small but noticeable default risk.
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Molecular Partners AG has total debt of 1.8m CHF. This includes both short-term (0 CHF) and long-term (1.8m CHF) debt.
You can find a full breakdown on its Balance Sheet.